Peroral Levosimendan in Chronic Heart Failure

• Status: Completed
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will investigate the efficacy of oral levosimendan in patients with chronic New York Heart Association (NYHA) IIIb-IV heart failure (HF) using a composite end-point evaluating patient symptoms, morbidity and mortality. The patients are on treatment for at least 6 months.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Orion Corporation, Orion Pharma
• Treatments: Simendan

Criteria

Inclusion Criteria:

• Diagnosed chronic heart failure

• Severe symptoms (NYHA IIIb-IV)

• Optimal on-going oral treatment for HF

• Left ventricular ejection fraction less than or equal to 30%

Exclusion Criteria:

• Severe obstruction of ventricular outflow tracts

• Acute myocardial infarction within 30 days before screening

• Cardiac surgery or coronary angioplasty within 30 days before screening